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Paradigms of public-private partnerships in end-stage renal dis- dialysis and transplantation become widely available. Al-
ease care: The National Kidney Foundation Singapore. Novel ready, marked differences in the availability of chronic
forms of funding chronic renal replacement therapy and other
dialysis care exist between developed and developing na-chronic kidney disease programs are urgently required in order
tions. In India and China, only 5 and 3 per million popula-to address the increasing global burden of end-stage renal
disease (ESRD). For areas of infectious disease control in less- tion (pmp), respectively, are accepted into dialysis pro-
developed countries, the formation of public-private partner- grams, as compared to 166 pmp in the USA [3]. Indeed, in
ships has successfully yielded short-term improvement in clini-
China, it has been estimated that the majority of incidentcal outcomes. This article reviews the concept of public-private
ESRD cases do not survive because of significantly re-partnerships and its various formats. We argue that similar
partnerships play an important role in addressing the public duced access to dialysis or transplantation that directly
health problem of chronic kidney disease. Through its estab- results from insufficient funds [4]. Thus, in less developedlishment of numerous paradigms of partnerships with private
countries where government funded ESRD care is re-for-profit corporations in building a nationwide chronic dialysis
program and through partnerships with other non-governmen- stricted, chronic dialysis is available only to those with
tal institutions and healthcare institutions in order to create a the economic means to pay for treatment [3]. In fact,
new entity characterized by a separate management structure, even in nations such as the United States where federalthe NKFS has been able to provide chronic dialysis care to over
support ensures sufficient funds for ESRD programs,70% of the country’s total ESRD population. This extensive
network of partnerships is currently being applied as the NKFS individual differences in socioeconomic status continue
continues to expand its programs to focus on the prevention to be associated with a wide variation in health outcomes
of chronic kidney disease at a nationwide level.
[5]. In a study of Medicare-eligible hemodialysis patients
within the United States, each USD$10,000 increase in
income was associated with a 5% reduction in mortality,Global projections consistently demonstrate an escala-
even after adjusting for clinical, behavioral and othertion in both the incidence and prevalence of end-stage
known predictors. Similar differences in long-term mor-renal disease (ESRD). Using data from the United States
bidity and mortality have been observed in other chronicRenal Data System (USRDS), the ESRD incidence in
diseases [6, 7].the US was estimated to increase following a linear trend
With the cost of care and the economics of ESRD being[1]. More importantly, the prevalence is predicted to in-
the primary barriers to widespread access to chronic re-crease in an exponential manner such that Medicare ex-
nal replacement therapy; with socioeconomic status be-penditures for ESRD are calculated to exceed USD$28
ing a definite factor affecting health outcomes, and withbillion by the year 2010 [1]. Similarly, global ESRD esti-
mates demonstrate an increase in the total ESRD popu- the global concern for the continued increase in the inci-
lation in the world, which will exceed 2 million patients dence and prevalence of ESRD, we propose that novel
and reach an annual global cost of US$75 billion dol- approaches to providing chronic disease care should be
lars [2]. considered. In this article, a unique paradigm of funding
The global burden of ESRD only serves to emphasize chronic dialysis care based entirely on the formation of
the need to explore alternative models of funding costly several forms of public-private partnerships will be pre-
chronic renal replacement therapy (RRT), so that chronic sented. This model, which continues to be a central and
evolving paradigm for the National Kidney Foundation
Singapore, illustrates the potential strength of such col-Key words: public-private partnership, ESRD, funding, social entre-
preneurship, prevention of renal disease. laborations in addressing priority health concerns in the
country [8]. 2003 by the International Society of Nephrology
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OVERVIEW OF PUBLIC-PRIVATE minimum set of elements that are required in order to
succeed. These include: a commonality of goals, strategyPARTNERSHIPS TO ADDRESS
and values; the formation of interpersonal relationshipsHEALTH CARE ISSUES
between partnering institutions; the creation of valueIn the last decade, global health care bodies, such
for both partners; and concrete guidelines to facilitateas the World Health Organization and the World Bank,
feedback and communication. It also is recognized thathave recognized that for many health care issues affect-
there is a need for agreement on defining criteria foring economically challenged regions in the world, cross-
the evaluation of the extent to which a partnership hassectoral collaboration between not-for-profit public in-
achieved its goals [10, 14, 15].stitutions and for-profit corporations is required [9]. This
relatively novel concept formalizes the sharing of exper- Global illustrations of successful partnerships
tise and resources toward the accomplishment of a com-
It is in the area of infectious disease in less-developedmon socially beneficial objective [10]. Beyond simply a
countries that global public-private partnerships are mostmatter of one partner providing funds or grants toward
firmly established. In a database of public-private part-the accomplishment of a particular initiative, these part-
nerships, the Initiative on Public-Private Partnershipsnerships are characterized by a balanced division of la-
for Health, where partnerships are classified accordingbor and resources, with a blurring of the conventional
to disease targets, over 70% of all listed initiatives targetboundaries that separate for-profit and non-profit orga-
tropical diseases, vitamin deficiency, AIDS, dehydrationnizations [9].
and other infectious-related diseases that affect less de-The major factor that gave rise to such partnerships
veloped countries [16]. These partnerships have tradi-is the recognition that for many large-scale health-related
tionally focused on new drug development for diseaseschallenges, conventional approaches to program devel-
that predominantly affect economically-disadvantagedopment traditionally carried out by the public sector can
individuals, and on the creation of drug delivery opera-only yield limited results [11]. Such partnerships recog-
tional systems to facilitate the distribution of existing
nize that although each founding partner may be driven
pharmaceutical agents [17].
by different ethics and overriding motivations, for the Two of the most recognized partnerships are the Mec-
purposes of a specific health care challenge, a convergence tizan Donation Program [12] and the International Tra-
of strategies and goals is appropriate [12]. It is also be- choma Initiative [14]. The Mectizan Donation Program
lieved that for both sectors, significant benefit can be is a partnership between Merck Pharmaceuticals and the
derived by each of the partnering institutions. For in- Task Force for Child Survival in order to systematically
stance, the public sector can gain knowledge and skills donate ivermectin for the control of a debilitating condi-
in areas such as product development, marketing, and tion, onchocerciasis, which if left untreated leads to
sales, whereas the private sector can benefit from in- blindness. As a result of this program, it is estimated that
creased exposure and improved community branding [9]. 200,000 individuals have been prevented from becoming
Public-private partnerships have been classified ac- blind [18]. Furthermore, the drug’s use in over 11 African
cording to different criteria. Buse and Walt divide public- nations is thought to have resulted in a significant reduc-
private partnerships according to: (1) degrees of com- tion in transmission rates of onchocerciasis [19]. Simi-
bined governance (equal negotiation capacity vs. delega- larly, the International Trachoma Initiative (ITI) was
tion), (2) nature of activity (consultative vs. operational), a partnership formed between the Clark Foundation,
and (3) goals of the partnership (product-focused, ser- traditionally a research funding body, and Pfizer Pharma-
vices-oriented, among others) [13]. In a description of the ceuticals, in order to make azithromycin widely available
International Trachoma Initiative, a joint venture be- for the control of trachoma, another condition that leads
tween the non-profit Clark Foundation and Pfizer Phar- to blindness and is highly prevalent in African, Middle
maceuticals, Barrett and others similarly use degrees of Eastern and certain Asian nations. Short-term clinical
collaboration as the basis of classifying public-private outcomes of the ITI have demonstrated up to 50% reduc-
partnerships [14]. In a concept known as the “collabora- tion in the prevalence of trachoma in pilot projects con-
tion continuum,” partnerships can be characterized as ducted in Morocco and Tanzania [14]. Common to these
solely grant giving at one end of the scale, progressing two partnerships is the identification of a unified mission:
to the “transactional stage” whereby partners combine the provision of a pharmacologically effective treatment
resources toward a common goal, to the “integrative to communities that could otherwise not afford the cost
stage” that is characterized by the merging of institu- of such treatment. Equally important is the recognition
tional resources in order to generate a new identity [15]. of each sector’s specific need in the formation of such a
Regardless of the categorization of public-private part- partnership; that is, the acknowledgment that a partner
nerships, lessons from the limited number of such part- enters an agreement for specific gains that may be unique
to the individual partner. For Pfizer or Merck, the specificnerships that exist worldwide suggest the need for a
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goal may be increased visibility or an enhanced public month (Singapore $1750) would need to be paid for out-
of-pocket in the absence of subsidy, solely for the directimage that may indirectly result in an increase in sales
of unrelated products, whereas for the Task Force for costs associated with chronic dialysis treatment.
With the above in mind, the NKFS set about establish-Child Survival or the Clark Foundation, the primary
motivation may be the actual provision of the specific ing what has become the largest single dialysis network in
Southeast Asia, which currently provides chronic dialysisdrug in order to achieve greater recognition of its impact
and contributions to society. care to over 70% of the country’s total ESRD population
[21]. It provides up to 96% subsidy for all direct costs re-Although the concepts of public-private partnership
have traditionally been applied predominantly to infec- lated to dialysis treatment, with intermediate clinical and
mortality outcomes that are at least comparable to thosetious diseases in developing nations, we believe that
these same strategies can be an effective means to ad- achieved in the United States (details on NKFS paradigm
of funding ESRD care and its resulting clinical outcomesdress the public health issue of chronic kidney disease
and its associated diseases. Furthermore, we argue that are in [8]). Furthermore, the program’s rehabilitation
outcomes demonstrate that close to 90% of ESRD pa-within an institution, several forms of public-private part-
nerships can exist simultaneously in order to address tients considered as eligible for employment [excluding
those older than 60 years of age (Singapore’s retirementa unifying problem: the provision of affordable renal
replacement therapy. Finally, we demonstrate from the age), students, housewives and the 4.4% assessed by the
medical staff as medically unfit for employment] are fullyexperience of the National Kidney Foundation Singa-
pore that implementing such partnerships can be of rele- or partially employed. In contrast, studies in the United
States of ESRD patients 62 years or younger demon-vance even in a developed nation such as Singapore.
strate employment rates ranging from 11 to 24% [22, 23].
This high employment rate has probably been achieved
THE NATIONAL KIDNEY FOUNDATION
through direct financial motivation of the ESRD popula-
SINGAPORE (NKFS) CLINICAL PROGRAMS
tion, in that patient subsidy is matched to an individual’s
The NKFS’ public-private partnerships are best viewed success at personal rehabilitation, as well as through
in the context of its clinical programs and other accom- partnerships with private corporations that do not dis-
plishments. The National Kidney Foundation Singapore, criminate against the employment of individuals on chronic
the largest charitable organization in the country, was dialysis.
founded in 1969 with an initial mandate of educating Because of the rising annual incidence of ESRD in
the Singapore public about ESRD [8]. One of its early Singapore, in general, and the increase in both the inci-
successes was its facilitation of the passage of the Human dence and prevalence of dialysis treatment at the NKF, in
Organ Transplant Act in 1987, which assumes that a Sin- particular [24], the NKFS expanded its focus to include
gaporean aged 21 to 60 years is presumed to be a kidney the prevention of kidney disease and its associated chronic
transplant donor unless a specific objection was made diseases [25]. Stepwise primary, secondary and tertiary
during the individual’s lifetime [20]. Singaporean Mus- prevention initiatives were designed to address obstacles
lims are currently excluded from participation because to care at each stage in the development of kidney dis-
of religious ideology, although the NKFS has initiated ease among individuals at risk for the development of
a campaign in partnership with the Muslim community ESRD. These include nationwide surveillance for urinary
in order to reexamine this exemption. abnormalities, hypertension, diabetes and other recog-
In 1987, because of the realization that over 95% of the nized risk factors for kidney disease, the development
country’s ESRD population was dying because of an in- of a network of NKFS Prevention Centers, which provide
ability to afford chronic renal replacement therapy, the secondary screening for detected abnormalities as well as
NKFS initiated a program to provide subsidized chronic comprehensive team-based care for patients with known
dialysis therapy. In Singapore, healthcare is predominantly diabetes and hypertension. The NKFS Prevention Pro-
financed by a mandatory medical savings account known gram is comprehensive in breadth, as well as in reach.
as Medisave, a monthly savings account that amounts to Already over 800,000 Singaporeans have participated in
6 to 8% of the individual’s income. For chronic replace- its nationwide screening program, representing over 30%
ment therapy, a maximum of US$257 per month (Singa- of the country’s total adult population in the year 2001.
pore $450) can be used for chronic dialysis. An additional Based on this screening program, novel predictors for
US$570 to $1430 per month (Singapore $1000 to $2500) proteinuria have been identified in this uniquely Asian
can be utilized from an optional medical insurance scheme population including mild elevations in systolic and dia-
that can be purchased from the government. However, stolic blood pressure, both extremes of body mass index,
40% of the total NKFS ESRD population do not have and a family history of renal disease [26]. Similarly, based
access to this medical insurance scheme. Indeed, for the on the NKFS pediatric screening program, a low current
body weight was identified as a significant predictor formajority of ESRD patients, an additional US$1000 per
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proteinuria [27]. Both short- and long-term clinical and number and scope of NKFS’ partnerships with corpora-
tions, healthcare institutions and other publicly fundedeconomic outcomes are being monitored in order to
evaluate the efficacy of this comprehensive prevention organizations, it is beyond the scope of this discussion to
describe each of the partnerships in detail. Instead, spe-program. Furthermore, clinical data derived from the
surveillance, as well as the intervention program, will be cific examples will be used to represent each type of
NKFS partnership.analyzed and incorporated as the prevention program
and the NKFS continue to evolve to respond to the
Partnership with corporationspopulation’s healthcare needs.
In its attempt to accomplish one of its missions, that
Social entrepreneurship at the NKFS: Developing is, the provision of highly standardized chronic dialysis
public-private partnerships to fund that is affordable to all, the NKFS recognized the need
chronic disease care to work with strategic partners that could share the risk
involved with establishing such a program on a massiveThe success of the NKFS as a charitable organization
is based on its recognition that not-for-profit organiza- scale. In the early stages of this program, the natural
choice for partners would be pharmaceutical companiestions are not only measured by the social impact that
they create [28], but through responsible and transparent that are actively engaged with manufacturing and distri-
bution of dialysis-related products. In the earliest formsuse of donated funds [8]. In addition, the NKFS recog-
nized early on that an entrepreneurial approach is vital of partnerships, the NKFS worked with companies such
as Fresenius, Inc. and Baxter, Inc., in order to provide di-to a charitable organization’s long-term sustainability. In-
deed, social entrepreneurship as a formal entity has only alysis machines at much reduced cost. Indeed, even re-
cently, in an initiative to expand national treatment op-recently attracted attention [29]. However, the NKFS
has long been oriented toward the identification of op- tions for ESRD, Baxter, Inc. formed a partnership with
NKFS in order to establish a national peritoneal dialysisportunity, the pursuit of innovation, the importance of a
clearly defined strategy, and the positioning of a proposi- program. This not only involves the provision of equip-
ment related to peritoneal dialysis, but also includes thetion (whether to another not-for-profit organization or
to a private corporation as a partner), characteristics that development of active training programs for both allied
health professionals and patients. Similarly, the NKFSdefine entrepreneurship and which have traditionally been
associated solely with for-profit corporations [28, 29]. identified a pharmaceutical company, Janssen-Cilag, as
a partner in its attempt to ensure the widespread avail-NKFS’ response to the nation’s healthcare needs, with the
accompanying recognition of the opportunity to impact ability of erythropoietin for chronic dialysis patients.
Through this partnership, ESRD patients of the NKFSon public health at a nationwide level, propelled its evo-
lution from a mere knowledge provider and a vehicle purchase erythropoietin at less than 50% of market costs.
In using terminology from the “collaboration contin-for public education, to its current status as the largest
single dialysis provider in Southeast Asia. Its mandate uum” [15], these relationships are representative of the
“transactional stage.” Indeed, more than simply reducingmost recently has expanded to include the implementa-
tion of programs and services to serve the entire popula- the cost of drugs, equipment or services, each of the part-
nering corporations continues to work with the NKFS intion at risk for chronic kidney disease through chronic
kidney disease prevention strategies. In its fundraising dialysis program development, patient and general popu-
lation education, as well as the training of allied healthinitiatives, the NKFS has always utilized fundamental
business methodologies such as customer relationship care professionals. This interest in continued partnership
has been further enhanced by the demonstration of con-and database marketing in order to generate funding for
its numerous clinical initiatives. Indeed, one of the most crete benefits for both sides of the partnership. For in-
stance, through the NKFS partnership with Janssen-novel aspects of the NKFS is its unique model of funding
kidney disease prevention and chronic dialysis care based Cilag, the foundation benefits by providing its patients
with an otherwise unaffordable drug, erythropoietin; whileentirely on charitable donations. The NKFS’ predomi-
nant strategy for generating sufficient funds in order to for Janssen-Cilag, the improved public relations may
translate to potentially improved sales to both the NKFSsustain its clinical programs is through the formation of
partnerships. NKFS’ partnerships are characterized by and the general public, even for unrelated products.
In response to the need to expand the national dialysisvarying degrees of collaborative relationship, represent-
ing each stage of the “collaboration continuum” as de- program, the NKFS proceeded to work with private cor-
porations. In order to address the need to build two tofined by Austin [15]. Established partnerships range from
conventional donations, progressing to active engagement three dialysis units each year, the NKFS has developed
partnerships with Singapore Airlines, the SUTL Grouptoward the implementation of a pre-defined collaborative
project, to full-scale integration with the resulting forma- of Companies, and Singapore Pools, among others. For
each of these partnerships, capital and recurrent costs oftion of separate institutions and joint ventures. Given the
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establishing the dialysis unit were provided by the pri- atric kidney disease and dialysis facility needed to be
created. The NKFS identified the National University Hos-vate corporation, whereas the NKFS was responsible for
developing the infrastructure, providing the technical pital (NUH) as the appropriate partner to establish this
program. The pediatrics department at the NUH wasknowledge, and fulfilling the manpower needs of the
facility. Each partnering corporation is involved further the logical partner, since it was the only facility in Singa-
pore with physicians and nurses appropriately trained towith clinical and rehabilitation outcomes monitoring of
the respective dialysis unit. Thus, by identifying private provide chronic dialysis to infants and small children. In
order to raise funds to support both capital and recurrentcorporations with a “social conscience,” the NKFS has
been able to ensure the availability of chronic dialysis costs for the facility, the NKFS worked with another not-
for-profit institution, the Shaw Foundation, with which thetreatment. In return, the private institution is ensured
the transparent and appropriate handling of funds to NKFS has had a long-standing partnership. With these
three organizations, the NKFS, the Shaw Foundation andachieve the collaborative mission of providing dialysis
care. Furthermore, their partnership with the NKFS en- the NUH, a new entity, the Children’s Kidney Center
was established. This facility, housed at the NUH com-hances their public image as a company that exemplifies
the best norms of philanthropy, which may indirectly plex, has separately defined medical and management
bodies, thereby reducing the likelihood that the Center’sresult in an improvement in the private corporation’s
own business. identity might be subsumed under that of either founding
institution. Partnerships with research and academic in-NKFS also has established partnerships with over 70
private small and large-scale businesses in Singapore stitutions are currently being evaluated also, including
the formation of a separate NKFS Molecular Researchtoward the development of an employment program for
patients with ESRD. These private corporations ac- and Genetics Unit in a partnership with one of the na-
tion’s leading research institutions.knowledge that even patients with chronic illnesses can
be contributing members to the workforce. To facilitate
Partnerships with other non-governmental organizationsthis process, the NKFS has a separate team that manages
a job placement service to match the skills of ESRD The NKFS has long recognized that the formation of
partnerships with other non-governmental organizationspatients to the requirements of the hiring company. In-
deed, the over 90% employment rate of the NKFS ESRD and organized religious groups represents a natural syn-
ergy and convergence of their respective missions andpopulation is partly attributable to this “Job Connec-
tions Program.” social responsibilities. Indeed, the most established and
successful of NKFS’ partnerships have been formed with
Partnership with healthcare institutions not-for-profit organizations such as the Shaw Founda-
tion, the SUTL Group of Companies, the Lee Founda-In addition to working in partnership with for-profit
corporations, the NKFS has established collaborative re- tion, and organized religious groups such as the Kwan
Im Thong Hood Cho Temple and the Buddhist Welfarelationships with healthcare institutions. In the initial
stages of the NKFS’ attempt at working with local ne- Services. For all of these organizations, there is an over-
riding commitment to benefit the community by utilizingphrology healthcare providers, its efforts met significant
resistance due to the creation of competition for services resources that may have been contributed by their re-
spective supporting donors, in the case of religious groups,with private dialysis centers. As a result, the NKFS estab-
lished independent partnerships with medical institu- or accumulated wealth, in the case of private foundations.
These partnerships encompass various components oftions outside Singapore, most notably that with the Brig-
ham and Women’s Hospital (Boston, MA, USA). Over the NKFS programs, with one institution generally work-
ing with the NKFS to accomplish more than a single ini-time, with increasing support from the local nephrology
community, the NKFS was able to formalize its relation- tiative. For example, the Kwan Im Thong Hood Cho Tem-
ple has worked with the NKFS to establish not only theship with local healthcare institutions. Hospital-based
nephrologists are now part of the staff that provides single largest dialysis unit in Asia, but to develop the
NKFS Nationwide Screening Program. Similarly, the Shawdirect patient care to NKFS dialysis patients.
Some of the NKFS’ partnerships with other healthcare Foundation worked with other institutions to provide
funding for the construction of the NKFS headquartersinstitutions represent the most formal of partnerships,
known as Austin’s “Integrative Stage” [15], in that sepa- building, in addition to establishing the Children’s Kid-
ney Center. Degrees of partnership vary according to therate joint ventures are created in order to fulfill a newly
identified mission. One primary focus for the NKFS’ pro- specific project rather than to the partnering institution.
For instance, the Kwan Im Thong Hood Cho Temple isgrams is the pediatric renal disease population. Given that
the only pediatric renal replacement program in the coun- intimately involved with the operations as well as clinical
outcomes of the nationwide screening program, whereastry was a small dialysis program established by the NKFS,
a more comprehensively structured and dedicated pedi- it plays a less prominent role in its dialysis program.
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Partnerships with private individuals ships with various institutions deserves consideration,
particularly in nations that have yet to establish dialysisOne of the NKFS strongest forms of partnerships in-
programs. For nations that have sufficient representationvolves its unique relationship with the general public.
of middle to upper socioeconomic classes, the NKFS ex-Regular personal communication with up to 65% of the
perience demonstrates that, given the proper infrastruc-country’s total population is ensured by traditional busi-
ture and communication methodologies, the generalness principles of customer relationship marketing. This
public is willing to partner with charitable foundations toprocess ensures that the individual’s communication
provide chronic disease care. For less-developed nationspreferences, whether through telephone conversation,
whose populations are significantly impoverished, thee-mail or direct mass mailing, are recognized and ad-
formation of public-private partnerships will be a uniquedressed. Fundamental to maintaining this partnership
challenge, since private corporations may not perceivewith the general public is the maintenance of transpar-
that a “social investment” in these markets is profitable.ency in the handling of funds and the fulfillment of delin-
However, with increasing globalization, the formation ofeated objectives. Indeed, details on the use of donated
public-private partnerships that do not recognize na-private funds are reported annually to the private indi-
tional boundaries may become increasingly more attrac-vidual donor in the form of an “Investment Report.”
tive as the impact of the partnership on international
business is no longer tightly linked to geographic consid-
SUMMARY erations. To this effect, the NKFS has formed a World
Kidney Fund with the specific aim of educating nephrol-With the recognition that chronic kidney disease is a
public health concern [30], novel strategies to address re- ogy health care providers in less-developed nations, im-
parting knowledge and skills relevant to fundraising, part-nal disease prevention and chronic renal replacement
therapy need to be identified and implemented. The NKFS nership development and business negotiation. Whether
or not such an initiative results in concrete benefits inhas demonstrated that public-private partnerships to ad-
dress urgent health care issues need not be limited to in- these nations will be closely monitored by the NKFS.
fectious diseases in developing nations. Indeed, the NKFS
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